Sequential personalized neoantigen vaccination following first‐line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma
Authors:
- 16 March 2026
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 159 (3) , 709-718
Abstract
Hepatocellular carcinoma (HCC) has limited therapeutic options in the advanced stages; although first‐line combinations of transarterial chemoembolization (TACE) with tyrosine kinase inhibitors (TKIs) and/or programmed cell death protein 1 (PD‐1) inhibitors show promise, their efficacy is constrained by inadequate tumor‐specific T‐cell infiltration. To address this limitation, we conducted an investigator‐initiated, single‐center clinical trial (ChiCTR2300067818) evaluating the safety, feasibility, and preliminary efficacy of sequential personalized neoantigen vaccination following TACE plus TKI/PD‐1‐based therapy in patients with advanced HCC. Whole‐exome and transcriptome sequencing identified patient‐specific neoantigens, which were synthesized as long peptides and formulated with dual adjuvants for subcutaneous administration. Among 10 initially enrolled patients, 4 received personalized vaccination after comprehensive screening, with 2 patients (N03 and N04) completing the full 8‐injection vaccination regimen. Sequential neoantigen vaccination demonstrated excellent safety profiles, with only mild injection‐site reactions observed. Both patients achieved partial response following vaccination. Interferon‐gamma Enzyme‐Linked ImmunoSpot assays confirmed robust neoantigen‐specific responses against multiple peptide pools in both patients. Dynamic monitoring revealed that serum alpha‐fetoprotein and Des‐gamma‐carboxy prothrombin levels correlated with clinical responses, declining significantly during vaccination. These findings demonstrate that sequential personalized neoantigen vaccination following first‐line TACE‐based therapy is safe, feasible, and capable of inducing potent tumor‐specific immune responses, supporting further investigation in larger clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China (82573538)
- National Natural Science Foundation of China (U22A20328)
- Fujian Provincial Health Technology Project (2022ZQNZD014)
- Fujian Provincial Health Technology Project (2024ZD01004)
This publication has 11 references indexed in Scilit:
- Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8+CD69+ T cellsJournal for ImmunoTherapy of Cancer, 2024
- Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinomaCancer Cell, 2024
- Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trialNature Medicine, 2024
- Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinomaNature Reviews Clinical Oncology, 2024
- Challenges in developing personalized neoantigen cancer vaccinesNature Reviews Immunology, 2023
- Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma modelsJournal for ImmunoTherapy of Cancer, 2022
- Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasionMolecular Cancer, 2021
- High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 + CD8 + T cellsGut, 2020
- fastp: an ultra-fast all-in-one FASTQ preprocessorBioinformatics, 2018
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012